Trials of lenalidomide in B-cell NHL included in analysis
| Treatment type/lymphoma subtype(s) . | Trial design . | Disease state . | Treatment . | Pts . | Avg. cycles per Pt . | Total Pt-cycles . | VTE event . | Prophylaxis . | Study ref. no. . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Single-agent lenalidomide | ||||||||||
| MCL | Prospective cohort | R/R | Lenalidomide | 134 | 3 | 402 | 10 | Aspirin, LMWH, or warfarin in high-risk patients | 10 | |
| RCT | R/R | Lenalidomide | 167 | 6 | 1002 | 18 | Aspirin; LMWH/warfarin if contraindicated | 11 | ||
| Follicular | RCT | R/R | Lenalidomide | 45 | 10 | 432 | 7 | Aspirin or LMWH in high-risk patients | 7 | |
| MALT | Prospective cohort | Mixed (untreated and R/R) | Lenalidomide | 18 | 5 | 86 | 0 | Aspirin | 12 | |
| DLBCL, MCL, follicular, transformed | Prospective cohort | R/R | Lenalidomide | 25 | 6 | 150 | 0 | None specified | 13 | |
| DLBCL, follicular, MCL, transformed | Prospective cohort | R/R | Lenalidomide | 49 | 5 | 246 | 2 | None specified | 14 | |
| DLBCL, MCL, follicular, transformed | Prospective cohort | R/R | Lenalidomide | 217 | 8 | 1688 | 5 | None specified | 2 | |
| Follicular, SLL, MZL | Prospective cohort | R/R | Lenalidomide | 43 | 6 | 243 | 3 | None specified | 3 | |
| Lenalidomide + biologic | ||||||||||
| DLBCL | Prospective cohort | R/R | Lenalidomide + rituximab | 17 | 6 | 107 | 0 | Aspirin | 15 | |
| Prospective cohort | R/R | Lenalidomide + rituximab | 23 | 4 | 92 | 0 | None specified | 16 | ||
| MCL | Prospective cohort | R/R | Bortezomib + lenalidomide | 53 | 6 | 294 | 3 | Aspirin or LMWH in high-risk patients | 17 | |
| Prospective cohort | Untreated | Lenalidomide + rituximab | 36 | 26 | 932 | 0 | Aspirin or LMWH | 5 | ||
| Prospective cohort | R/R | Lenalidomide + rituximab | 44 | 9 | 379 | 3 | Not required | 18 | ||
| Prospective cohort | R/R | Lenalidomide + dexamethasone | 33 | 7 | 230 | 0 | LMWH | 19 | ||
| Follicular | RCT | R/R | Lenalidomide + rituximab | 46 | 10 | 441 | 2 | Aspirin or LMWH in high-risk patients | 7 | |
| Prospective cohort | Untreated | Lenalidomide + rituximab + ibrutinib | 10 | 18 | 180 | 0 | Aspirin, LMWH if contraindicated | 20 | ||
| Follicular, MCL, CLL, lymphoblastic, MZL | Prospective cohort | R/R | Lenalidomide + rituximab | 50 | 16 | 777 | 2 | None specified | 21 | |
| DLBCL, follicular, transformed | Prospective cohort | R/R | Lenalidomide + rituximab | 45 | 4 | 185 | 4 | Not required | 22 | |
| Lenalidomide + chemotherapy | ||||||||||
| DLBCL | Prospective cohort | R/R | RICE + lenalidomide | 8 | 7 | 54 | 0 | Aspirin; LMWH if contraindicated | 23 | |
| Prospective cohort | R/R | Lenalidomide + R-ESHAP | 19 | 3 | 56 | 2 | Aspirin or LMWH in high-risk patients | 24 | ||
| Prospective cohort | Untreated | Lenalidomide + R-CHOP | 64 | 6 | 356 | 1 | Aspirin | 25 | ||
| MCL | Prospective cohort | Untreated | Bendamustine + lenalidomide + rituximab | 51 | 8 | 397 | 3 | Aspirin or LMWH | 26 | |
| Prospective cohort | Bendamustine + lenalidomide + rituximab | 42 | 14 | 577 | 0 | None specified | 27 | |||
| DLBCL, follicular | Prospective cohort | Untreated | Lenalidomide + R-CHOP21 | 49 | 6 | 277 | 2 | LMWH | 28 | |
| DLBCL, MZL, HL, transformed, Sezary, Waldenstrom | Prospective cohort | R/R | Bendamustine + lenalidomide + rituximab | 20 | 6 | 120 | 1 | None specified | 29 | |
| DLBCL, transformed, follicular | Prospective cohort | R/R | Lenalidomide + rituximab + bendamustine | 41 | 4 | 155 | 0 | None specified | 30 | |
| DLBCL, follicular | Prospective cohort | Untreated | Lenalidomide + R-CHOP | 24 | 6 | 133 | 2 | Aspirin | 31 | |
| Follicular, MZL, SLL, Waldenstrom | Prospective cohort | Untreated | Lenalidomide + rituximab + dexamethasone + cyclophosphamide | 33 | 6 | 198 | 5 | Aspirin; LMWH/warfarin if contraindicated | 32 | |
| MCL, MZL, SLL, DLBCL, transformed | Prospective cohort | Untreated | Lenalidomide + R-CHOP | 27 | 4 | 143 | 2 | Aspirin | 33 |
| Treatment type/lymphoma subtype(s) . | Trial design . | Disease state . | Treatment . | Pts . | Avg. cycles per Pt . | Total Pt-cycles . | VTE event . | Prophylaxis . | Study ref. no. . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Single-agent lenalidomide | ||||||||||
| MCL | Prospective cohort | R/R | Lenalidomide | 134 | 3 | 402 | 10 | Aspirin, LMWH, or warfarin in high-risk patients | 10 | |
| RCT | R/R | Lenalidomide | 167 | 6 | 1002 | 18 | Aspirin; LMWH/warfarin if contraindicated | 11 | ||
| Follicular | RCT | R/R | Lenalidomide | 45 | 10 | 432 | 7 | Aspirin or LMWH in high-risk patients | 7 | |
| MALT | Prospective cohort | Mixed (untreated and R/R) | Lenalidomide | 18 | 5 | 86 | 0 | Aspirin | 12 | |
| DLBCL, MCL, follicular, transformed | Prospective cohort | R/R | Lenalidomide | 25 | 6 | 150 | 0 | None specified | 13 | |
| DLBCL, follicular, MCL, transformed | Prospective cohort | R/R | Lenalidomide | 49 | 5 | 246 | 2 | None specified | 14 | |
| DLBCL, MCL, follicular, transformed | Prospective cohort | R/R | Lenalidomide | 217 | 8 | 1688 | 5 | None specified | 2 | |
| Follicular, SLL, MZL | Prospective cohort | R/R | Lenalidomide | 43 | 6 | 243 | 3 | None specified | 3 | |
| Lenalidomide + biologic | ||||||||||
| DLBCL | Prospective cohort | R/R | Lenalidomide + rituximab | 17 | 6 | 107 | 0 | Aspirin | 15 | |
| Prospective cohort | R/R | Lenalidomide + rituximab | 23 | 4 | 92 | 0 | None specified | 16 | ||
| MCL | Prospective cohort | R/R | Bortezomib + lenalidomide | 53 | 6 | 294 | 3 | Aspirin or LMWH in high-risk patients | 17 | |
| Prospective cohort | Untreated | Lenalidomide + rituximab | 36 | 26 | 932 | 0 | Aspirin or LMWH | 5 | ||
| Prospective cohort | R/R | Lenalidomide + rituximab | 44 | 9 | 379 | 3 | Not required | 18 | ||
| Prospective cohort | R/R | Lenalidomide + dexamethasone | 33 | 7 | 230 | 0 | LMWH | 19 | ||
| Follicular | RCT | R/R | Lenalidomide + rituximab | 46 | 10 | 441 | 2 | Aspirin or LMWH in high-risk patients | 7 | |
| Prospective cohort | Untreated | Lenalidomide + rituximab + ibrutinib | 10 | 18 | 180 | 0 | Aspirin, LMWH if contraindicated | 20 | ||
| Follicular, MCL, CLL, lymphoblastic, MZL | Prospective cohort | R/R | Lenalidomide + rituximab | 50 | 16 | 777 | 2 | None specified | 21 | |
| DLBCL, follicular, transformed | Prospective cohort | R/R | Lenalidomide + rituximab | 45 | 4 | 185 | 4 | Not required | 22 | |
| Lenalidomide + chemotherapy | ||||||||||
| DLBCL | Prospective cohort | R/R | RICE + lenalidomide | 8 | 7 | 54 | 0 | Aspirin; LMWH if contraindicated | 23 | |
| Prospective cohort | R/R | Lenalidomide + R-ESHAP | 19 | 3 | 56 | 2 | Aspirin or LMWH in high-risk patients | 24 | ||
| Prospective cohort | Untreated | Lenalidomide + R-CHOP | 64 | 6 | 356 | 1 | Aspirin | 25 | ||
| MCL | Prospective cohort | Untreated | Bendamustine + lenalidomide + rituximab | 51 | 8 | 397 | 3 | Aspirin or LMWH | 26 | |
| Prospective cohort | Bendamustine + lenalidomide + rituximab | 42 | 14 | 577 | 0 | None specified | 27 | |||
| DLBCL, follicular | Prospective cohort | Untreated | Lenalidomide + R-CHOP21 | 49 | 6 | 277 | 2 | LMWH | 28 | |
| DLBCL, MZL, HL, transformed, Sezary, Waldenstrom | Prospective cohort | R/R | Bendamustine + lenalidomide + rituximab | 20 | 6 | 120 | 1 | None specified | 29 | |
| DLBCL, transformed, follicular | Prospective cohort | R/R | Lenalidomide + rituximab + bendamustine | 41 | 4 | 155 | 0 | None specified | 30 | |
| DLBCL, follicular | Prospective cohort | Untreated | Lenalidomide + R-CHOP | 24 | 6 | 133 | 2 | Aspirin | 31 | |
| Follicular, MZL, SLL, Waldenstrom | Prospective cohort | Untreated | Lenalidomide + rituximab + dexamethasone + cyclophosphamide | 33 | 6 | 198 | 5 | Aspirin; LMWH/warfarin if contraindicated | 32 | |
| MCL, MZL, SLL, DLBCL, transformed | Prospective cohort | Untreated | Lenalidomide + R-CHOP | 27 | 4 | 143 | 2 | Aspirin | 33 |
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; LMWH, low-molecular-weight heparin; MALT, mucosa-associated lymphoid tissue; MZL, marginal zone lymphoma; Pt(s), patient(s); R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-CHOP21, R-CHOP repeated every 21 days; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin; R/R, relapsed/refractory; RCT, randomized controlled trial; ref. no., reference number; RICE, rituximab, ifosfamide, carboplatin, etoposide; SLL, small lymphocytic lymphoma.